FILE PHOTO: The company’s logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann Post navigation Novartis drug cuts recurrence risk by 25% in early-stage breast cancer